Endocytosis and mitogenic signaling

Current Opinion in Cell Biology

Volumn 11, Issue 4, 1999, Pages 483-488

  Fiore, Pier Paolo Di ^a   Gill, Gordon N ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLATHRIN; RECEPTOR;

CANCER; CELL MEMBRANE; CELL PROLIFERATION; CELL SURFACE; ENDOCYTOSIS; INTERNALIZATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033180472     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(99)80069-6     Document Type: Article

References (57)

1. Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, Rosenfeld MG: Ligand-induced transformation by a noninternalizing EGF receptor. Science 1990, 247:962-964.
2. French AR, Tadaki DK, Niyogi SK, Lauffenburger DA: Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand in interaction. J Biol Chem 1995, 270:4334-4340.
3. Vieira AV, Lamaze C, Schmid SL: Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 1996, 274:2086-2089.
4. Simons K, Ikonene E: Functional rafts in cell membranes. Nature 1997, 387:569-572.
5. Okamoto T, Schlegel A, Scherer PE, Lisanti MP: Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane. J Biol Chem 1998, 273:5419-5422.
6. Di Fiore PP, Pelicci PG, Sorkin A: EH: A novel protein-protein interaction domain potentially involved in intracellular sorting. Trends Biochem Sci 1997, 22:411-413.
7. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y: c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998, 12:3663-3674. The authors provide evidence that c-Cbl sorts EGFR in the endosome compartment for degradation and that oncogenic mutants of Cbl interfere to favor recycling of EGFR. Interference with a genetically defined negative regulator of EGFR signaling results in enhanced mitogenesis due to altered endocytic trafficking.
8. Yoon CH, Lee J, Jongeward GD, Sternberg PW: Similarity of sli-1, a regulator of vulval development in C. elegans to the mammalian proto-oncogene c-cbl. Science 1995, 269:1102-1105.
9. Meisner H, Daga A, Buxton J, Fernandez B, Chawla A, Banerjee U, Czech MP: Interactions of Drosophila Cbl with epidermal growth factor receptors and role of Cbl in R7 photoreceptor cell development Mol Cell Biol 1997, 17:2217-2222.
10. Ota Y, Samelson LE: The product of the proto-oncogene c-cbl: A negative regulator of Syk tyrosine kinase. Science 1997, 276:418-420.
11. Wu C, Butz S, Ying YS, Anderson RGW: Tyrosine kinase receptors concentrated in caveolae-like domains from neuronal plasma membrane. J Biol Chem 1997, 272: 3554-3559.
12. Mineo C, James GL, Smart EJ, Anderson RGW: Localization of epidermal growth factor-stimulated Ras/Raf-1 interaction to caveolae membrane. J Biol Chem 1996, 271:11930-11935.
13. Huang HJ Su, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK: The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997, 272:2927-2935.
14. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G: All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 1996, 271:5251-5257.
15. Ohno H, Stewart J, Fournier MC, Bosshart H, Rhee I, Miyatake S, Saito T, Gallusser A, Kirchhausen T, Bonifacino JS: Interaction of tyrosine-based sorting signals with clathrin-associated proteins. Science 1995, 269:1872-1875.
16. Owen DJ, Evans PR: A structural explanation for the recognition of tyrosine-based endocytic signals. Science 1998, 282:1327-1332. The crystal structure of the μ2 subunit of AP2 complexed with peptides corresponding to the YXXΦ motifs of EGFR and TGN38. This study also identified μ2 dimers that would increase the affinity for binding receptor dimers.
17. Sorkin A, McKinsey T, Shin W, Kirchhausen T, Carpenter G: Stoichiometric interaction of the epidermal growth factor receptor with the clathrin-associated protein complex AP-2. J Biol Chem 1995, 270:619-625.
18. Nesterov A, Carter RE, Sorkina T, Gill GN, Sorkin A: Inhibition of the receptor-binding function of clathrin adaptor protein AP2 by dominant-negative μ2 subunit and its effect on endocytosis. EMBO J 1999, 18:2489-2499.
19. Nesterov A, Wiley HS, Gill GN: Ligand-induced endocytosis of epidermal growth factor receptors that are defective in binding adaptor proteins. Proc Natl Acad Sci USA 1995, 92:8719-8723.
20. Kibbey RG, Rizo J, Gierasch LM, Anderson RG: The LDL receptor clustering motif interacts with the clathrin terminal domain in a reverse turn conformation. J Cell Biol 1998, 142:59-67.
21. Rapoport I, Chen YC, Cupers P, Shoelson SE, Kirchhausen T: Dileucine-based sorting signals bind to the β chain of AP-1 at a site distinct and regulated differently from the tyrosine-based motif-binding site. EMBO J 1998, 17:2148-2155.
22. Piguet V, Chen YL, Mangasarian A, Foti M, Carpentier JL, Trono D: Mechanism of Nef-induced CD4 endocytosis; Nef connects CD4 with the μ chain of adaptor complexes. EMBO J 1998, 17:2472-2481.
23. Chen H, Fre' S, Slepnev VI, Capua MR, Takei K, Butler MH, Di Fiore PP, De Camilli P: Epsin is an EH-domain-binding protein implicated in clathrin-mediated endocytosis. Nature 1998, 394:793-797. Cloning and characterization of epsin, an Eps15 EH domain and α-adaptin binding protein that functions as accessory protein for endocytosis via clathrin-coated pits.
24. Salcini AE, Confalonieri S, Doria M, Santolini E, Tassi E, Minenkova O, Cesareni G, Pelicci PG, Di Fiore PP: Binding specificity and in vivo targets of EH domains, a novel protein - Protein interaction module. Genes Dev 1997, 11:2239-2249.
25. Chen H, Slepnev VI, Di Fiore PP, De Camilli P: The interaction of epsin and Eps15 with the clathrin adaptor AP-2 is inhibited by mitotic phosphorylation and enhanced by stimulation-dependent dephosphorylation in nerve terminals. J Biol Chem 1999, 274:3257-3260.
26. Stenmark H, Aaasland R, Toh BH, D'Arrigo A: Endosomal localization of the autoantigen EEA1 is mediated by a zinc-binding FYVE finger. J Biol Chem 1996, 271:24028-24054.
27. Patki V, Lawe DC, Corvera S: A functional PtdIns(3)P binding motif. Nature 1998, 394:433-434.
28. Burd CG, Emr SD: Phosphatidylinositol (3)-phosphate signaling mediated by specific binding to RING FYVE domains. Mol Cell 1998, 2:157-162. Demonstrates that FYVE fingers specifically recognize Ptdlns(3)P and that association of FYVE finger proteins with endosome vesicles requires the Pl3-K Vps34p.
29. Gaullier JM, Simonsen A, D'Arrigo A, Bremnes B, Stenmark H: FYVE fingers bind Ptdlns(3)P. Nature 1998 394:432-433.
30. Simonsen A, Lippe R, Christoforidis S, Gaullier JM, Brech A, Callaghan J, Toh BH, Murphy C, Zerial M, Stenmark H: EEA1 links pl(3) K function to Rab5 regulation of endosome fusion. Nature 1998, 394:494-498. Provides evidence that binding of Rab5-GTP, and Ptdlns(3)P target EEA1 to early endosome membranes to mediate vesicle fusion.
31. Mills IG, Jones AT, Clague MJ: Involvement of the endosomal autoantigen EEA1 in homotypic fusion of early endosomes. Curr Biol 1998, 8:881-884.
32. Floyd S, De Camilli P: Endocytosis proteins and cancer: A potential link? Trends Cell Biol 1998, 8:299-301.
33. Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA, Bell S, McKenzie AN, King G, Rabbitts TH: An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes. Cell 1996, 85:853-861.
34. Dreyling MH, Schrader K, Fonatsch C, Schlegelberger B, Haase D, Schoch C, Ludwig W, Loffler H, Buchner T, Wormann B et al.: MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): Both rearrangements are associated with a poor prognosis. Blood 1998, 91:4662-4667.
35. Rotman G, Shiloh Y: ATM: From gene to function. Hum Mol Genet 1998, 7:1555-1563.
36. Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, Byrd PJ, Moss PA, Taylor AM: Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999, 35:26-29.
37. Stoppa-Lyonnet D, Soulier J, Lauge A, Dastot H, Garand R, Sigaux F, Stern MH: Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood 1998, 91:3920-3926.
38. Bullrich F, Rasio D, Kitada S, Starostik P, Kipps T, Keating M, Albitar M, Reed JC, Croce CM: ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 1999, 59:24-27.
39. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C, Abraham RT: A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999, 13:152-157.
40. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, Taya Y, Gabrielli B, Chan D, Lees-Miller SP, Lavin MF: ATM associates with and phosphorylates p53: Mapping the region of interaction. Nat Genet 1998, 20:398-400.
41. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD: Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998, 28:1677-1679.
42. Lim DK, Kirsch DG, Canman CE, Ahn J-H, Ziv Y, Newman LS, Darnell RB, Shiloh Y, Kastan MB: ATM binds to β-adaptin in cytoplasmic vesicles. Proc Natl Acad Sci USA 1998, 95:10146-10151. The ataxia telangiectasia mutated protein (ATM) binds in vivo and in vitro to β-adaptin and co-localizes with it in cytoplasmic vesicles, suggesting a role for this cancer predisposition gene in vesicular transport.
43. Peyrard M, Fransson I, Xie YG, Han FY, Ruttledge MH, Swahn S, Collins JE, Dunham I, Collins VP, Dumanski JP: Characterization of a new member of the human beta-adaptin gene family from chromosome 22q12, a candidate meningioma gene. Hum Mol Genet 1994, 3:1393-1399.
44. Young J, Povey S: The genetic basis of tuberous sclerosis. Mol Med Today 1998, 4:313-319.
45. The European Chromosome 16 Tuberous Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993, 75:1305-1315.
46. Van Slegtenhorst M, De Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, Van den Ouweland A, Halley D, Young J et al.: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277:805-808.
47. Lininger RA, Park WS, Man YG, Pham T, MacGrogan G, Zhuang Z, Tavassoli FA: LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast. Hum Pathol 1998, 29:1113-11138.
48. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP: Evidence that lymphangiomyomatosis is caused by TSC2 mutations: Chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998, 62:810-815.
49. Xiao GH, Shoarinejad F, Jin F, Golemis EA, Yeung RS: The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J Biol Chem 1997, 272:6097-6100.
50. Van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, Van den Ouweland A, Reuser A, Sampson J, Halley D, Van der Sluijs P: Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 1998, 7:1053-1057. Demonstrates physical association in vivo between hamartin and tuberin, mediated by their coiled-coil regions. The study provides a molecular basis for the long-postulated co-localization of the two proteins in the same pathway.
51. Plank TL, Yeung RS, Henske EP: Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res 1998, 58:4766-4770.
52. Ohno M, Fornerod M, Mattaj IW: Nucleocytoplasmic transport: The last 200 nanometers. Cell 1998, 92:327-336.
53. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ: Nucleocytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998, 17:554-564. The hdm2 oncoprotein shuttles between the nucleus and the cytoplasm and its export is blocked by inhibitors of Rev export. The export function of hdm2 is required to accelerate p53 degradation and blockade of the Rev pathway inhibits negative regulation of hdm2 on p53 transcriptional activity.
54. Freedman DA, Levine AJ: Nuclear export is required for degradation of endogenous p53 by MDM2. Mol Cell Biol 1998, 18:7288-7293.
55. Juven-Gerson T, Shifman O, Unger T, Elkeles A, Haupt Y, Oren M: The mdm2 oncoprotein interacts with the cell fate regulator NUMB. Mol Cell Biol 1998, 18:3974-3982. Mdm2 binds to NUMB and causes translocation of the latter to the nucleus. This event is associated with a reduction in the levels of NUMB. Degradation of NUMB might be part of the oncogenic action of mdm2.
56. Ullman KS, Powers MA, Forbes DJ: Nuclear export receptors: From importin to exportin. Cell 1997, 90:967-970.
57. Soucek T, Yeung RS, Hengstschlager M: Inactivation of the cyclin dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci USA 1998, 95:15653-15658. Loss of TSC2 causes instability of the p27 negative growth regulator and resistance to the activity of ectopic p27. In TSC2-negative cells p27 is mislocalized to the cytosol where it might be degraded.